We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
South Korean group makes Covid-19 treatments for the UK’s GSK and AstraZeneca
South Korean biotech stocks have been a favourite of retail investors even before the pandemic
Prosecutors grill Samsung Electronics president Chung Hyun-ho over alleged $3.9bn fraud
South Korean prosecutors say staff were ordered to destroy or conceal data
The staff of Samsung biopharmaceutical unit are accused of destroying evidence
Stock exchange to monitor company’s efforts to boost management transparency for 3 years
High-growth drugs unit represented group’s best effort to diversify out of electronics
The company is accused of having inflated the value of an affiliate group
South Korean regulator says biopharma company dropped crucial information on joint venture
BioLogics changed the way it valued its stake in drugmaker Samsung Bioepis in 2015
Regulators are right to investigate but biotech company can make a good case for the defence
Shares in biopharma unit down by as much as 20%
Biologics listing expected to raise Won2tn-Won3tn as parent group’s main growth driver
International Edition
